Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RhoC modulates cell junctions and Type I interferon response in aggressive breast cancers

ABSTRACT: RhoC modulates cell junctions and Type I interferon response in aggressive breast cancers

PROVIDER: PRJNA733664 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14685300_1.fastq.gz	Fastqsanger.gz
	SRR14685300_2.fastq.gz	Fastqsanger.gz
	SRR14685301_1.fastq.gz	Fastqsanger.gz
	SRR14685301_2.fastq.gz	Fastqsanger.gz
	SRR14685254_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 96

Similar Datasets

RhoC modulates cell junctions and Type I interferon response in aggressive breast cancers

Project description:Metastases are the leading cause of death in cancer patients. RhoC, a member of the Rho GTPase family, has been shown to facilitate metastasis of aggressive breast cancer cells by influencing motility, invasion, and chemokine secretion, but as yet there is no integrated model of the precise mechanism of how RhoC promotes metastasis. A common phenotypic characteristic of metastatic cells influenced by these mechanisms is dysregulation of cell-cell junctions. Thus, we set out to study how RhoA- and RhoC-GTPase influence the cell-cell junctions in aggressive breast cancers. We demonstrate that CRISPR-Cas9 knockout of RhoC in SUM 149 and MDA 231 breast cancer cells results in increased normalization of junctional integrity denoted by junctional protein expression/colocalization. In functional assessments of junction stability, RhoC knockout cells have increased barrier integrity compared to wild-type cells as measured by the FITC-Dextran leakage assay, and increased cell-cell adhesion as measured by fluorimetric centrifugation assay. Whole transciptome RNA sequencing demonstrate decreased expression of Type I interferon-stimulated genes in RhoC knockout cells compared to wild-type, and subsequent treatment with interferon-alpha resulted in significant increases in adhesion and decreases in invasiveness of wild-type cells and a dampened response to interferon-alpha stimulation with respect to adhesion and invasiveness in RhoC knockout cells. We delineate a key role of RhoC-GTPase in modulation of junctions and response to interferon, which supports inhibition of RhoC as a potential anti-invasion therapeutic strategy.

2021-06-07 | GSE175787 | GEO

RhoC Modulates Cell Junctions and Type I Interferon Response in Aggressive Breast Cancers.

Project description:Metastases are the leading cause of death in cancer patients. RhoC, a member of the Rho GTPase family, has been shown to facilitate metastasis of aggressive breast cancer cells by influencing motility, invasion, and chemokine secretion, but as yet there is no integrated model of the precise mechanism of how RhoC promotes metastasis. A common phenotypic characteristic of metastatic cells influenced by these mechanisms is dysregulation of cell-cell junctions. Thus, we set out to study how RhoA- and RhoC-GTPase influence the cell-cell junctions in aggressive breast cancers. We demonstrate that CRISPR-Cas9 knockout of RhoC in SUM 149 and MDA 231 breast cancer cells results in increased normalization of junctional integrity denoted by junction protein expression/colocalization. In functional assessments of junction stability, RhoC knockout cells have increased barrier integrity and increased cell-cell adhesion compared to wild-type cells. Whole exome RNA sequencing and targeted gene expression profiling demonstrate decreased expression of Type I interferon-stimulated genes in RhoC knockout cells compared to wild-type, and subsequent treatment with interferon-alpha resulted in significant increases in adhesion and decreases in invasiveness of wild-type cells and a dampened response to interferon-alpha stimulation with respect to adhesion and invasiveness in RhoC knockout cells. We delineate a key role of RhoC-GTPase in modulation of junctions and response to interferon, which supports inhibition of RhoC as a potential anti-invasion therapeutic strategy.

| S-EPMC8428533 | biostudies-literature

The landscape of alternative splicing in aggressive prostate cancers

Project description:The landscape of alternative splicing in aggressive prostate cancers

| PRJNA594270 | ENA

ENHANCED INTERFERON-SENSING BY AGGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

Project description:ENHANCED INTERFERON-SENSING BY AGGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

| PRJNA807146 | ENA

5-hydroxymethylation highlights the heterogeneity in keratinization and cell junctions in head and neck cancers

Project description:5-hydroxymethylation highlights the heterogeneity in keratinization and cell junctions in head and neck cancers

| PRJNA602545 | ENA

HSP90 specific nIR probe identifies aggressive prostate cancers: a translational study from preclinical models to a human pilot study

Project description:Current screening modalities for prostate cancer rely on serologic testing for PSA and transrectal biopsy; however, many prostate cancers behave indolently.Because aggressively growing tumors depend on oncogenic drivers, we hypothesized that we could identify early, but aggressive prostate cancer,by an imaging modality targeting Hsp90, a chaperone for many molecules involved in oncogenic signaling. Previously we observedgreater avidity ofa probe,consisting of a near infrared dye tethered to an Hsp90 inhibitor,for cancers with greatermetastatic potential. We now report that an Hsp90 inhibitor-linked near infrared dye with greater tissue penetration could detect prostate cancers in preclinical models and in a phase I human clinical trial. These data, demonstrating specific uptake into aggressive tumors, in conjunction with our prior observations on photodynamic therapy guided by Hsp90 expression support a theranostic approach todetect and treatearly aggressive prostatecancers.

2022-01-01 | GSE164865 | GEO

Interferon Regulatory Factor 4 Modulates Epigenetic Silencing and Cancer-Critical Pathways in Melanoma Cells

Project description:Interferon Regulatory Factor 4 (IRF4) is a transcription factor initially identified as a key controller in lymphocyte differentiation and function, and subsequently as a dependency factor and therapy target in lymphocyte-derived cancers. In melanocytes, IRF4 takes part in the regulation of pigmentation. While numerous genetic studies have implicated IRF4 also in melanoma skin cancers, how IRF4 contributes to melanoma has remained largely elusive. In this study, we first confirmed that not only IRF4 expression is common in melanoma, but also IRF4 can act as a dependency factor for melanoma cells. Furthermore, to discover the functions of IRF4 in melanoma cells, we analyzed IRF4 target genes, which pointed to IRF4 as an upstream regulator of epigenetic silencing. Accordingly, we show that IRF4 regulates the expression of essential factors for DNA methylation (DNMT1, DNMT3B, UHFR1) and for repressive histone H3 lysine 27 methylation (EZH2), and consequently, the levels of the corresponding methylation marks. Moreover, expression of several tumor suppressor genes known to be silenced by these epigenetic modifications are regulated by IRF4. These include cyclin-dependent kinase inhibitors, PI3K pathway regulator PTEN, and primary cilium component WDR19. As a result, IRF4-dependent epigenetic regulation in melanoma cells modulates the activity of key oncogenic pathways, such as WNT/b-Catenin and PI3K-AKT, impacting on cell proliferation and survival. Moreover, IRF4 modulates the activity of pertinent epigenetic drugs in melanoma cells, encouraging further studies on the therapeutic targeting of IRF4 in melanoma.

2024-07-01 | GSE244460 | GEO

Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19

Project description:Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19

| PRJNA662785 | ENA

Mitochondrial aconitase (ACO2) modulates iron homeostasis and is associated with outcomes in poor prognosis aggressive non-small cell lung cancer

Project description:NSCLC accounts for 85% of lung cancers, the most frequently diagnosed and leading cause of cancer related death. An ACO2-iron acis regulates intracellular iron and consequently the particularly aggressive phenotype associated with NSCLC engraftment and poor prognosis. These findings suggest that NSCLC stratified by ACO2 protein level may benefit from treatments that target iron homeostasis.

2022-09-19 | PXD028556 | Pride

Chromosomal changes in aggressive breast cancers with basal-like features

Project description:Chromosomal changes in human aggressive breast cancer samples with basal-like features were detected using 44K oligo array CGH Keywords: DNA copy number change

2008-09-04 | GSE12659 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data